Bcr-Abl causes chronic myelogenous leukemia, a myeloproliferative disorder characterized by clonal expansion of hematopoietic progenitor cells. In this study, inducible expression of Bcr-Abl in TonB.210 cells is associated with increased production of intracellular reactive oxygen species (ROS), which is thought to play a role in survival signaling when generated at specific levels. Elevated ROS in Bcr-Abl-expressing cells were found to activate PI3k/Akt pathway members such as Akt and GSK3b as well as downstream targets b-catenin and Mcl-1. The activation of these proteins was inhibited by the flavoprotein inhibitor diphenyleneiodonium, which is commonly used to inhibit NADPH oxidase (Nox). This indicated that increased ROS might be related to increased activity of one member of the Nox family. Knock-down experiments using siRNA suggest that Nox-4 is the main source of increased ROS following Bcr-Abl expression. We showed that Bcr-Abl-induced ROS could also increase survival pathway signaling through redox inhibition of PP1a, a serine threonine phosphatase that negatively regulates the PI3k/Akt pathway. Overall our results demonstrate that Bcr-Abl expression increases Nox-4-generated ROS, which in turn increases survival signaling through PI3k/Akt pathway by inhibition of PP1a, thus contributing to the high level of resistance to apoptosis seen in these Bcr-Abl-expressing cells.
Introduction
Chronic myeloid leukemia (CML) is a myeloproliferative disorder characterized by increased proliferation of hematopoietic progenitor cells in the bone marrow. The underlying cause of CML is a characteristic reciprocal translocation between chromosomes 9 and 22, t(9;22)(q34;q11), known as the Philadelphia chromosome, 1 which generates the active chimeric kinase Bcr-Abl protein. 2 The PI3k/Akt pathway is constitutively active in CML cells and plays a major role in cell survival. On activation, Akt phosphorylates key survival proteins such as the transcription factor regulator glycogen synthase kinase 3b (GSK3b) which in turn regulates Mcl-1 and other downstream proteins, resulting in decreased cell susceptibility to apoptosis. 3 Multiple steps along the PI3k/Akt survival pathway are negatively regulated by phosphatases. For example, PP1a and PP2A have been shown to dephosphorylate Akt (for review, see Millward et al. 4 ) resulting in a decrease of Akt transduced survival signal. It has been demonstrated in vitro that hydrogen peroxide can reversibly block some of the main serine/threonine phosphatases such as PP2A and PP1a. 5, 6 This highlights the potential importance that oxidative modification of phosphatases by reactive oxygen species (ROS) may have in maintaining the elevated activity of Akt in CML cells. Besides mitochondria, one source of ROS in the cell is the family of transmembrane proteins termed Nox (NADPH oxidases). Seven homologs are known: Nox-1, Nox-2, Nox-3, Nox-4, Nox-5, Duox1 and Duox2 (for reviews, see Bedard and Krause 7 and Lambeth 8 ). ROS, in particular hydrogen peroxide, generated by this family of proteins has been shown to be involved in the regulation of various intracellular signaling pathways. 7 Sattler et al. 9 demonstrated that cells constitutively expressing Bcr-Abl had higher levels of ROS compared with untransformed cells and this led to a substantial reduction in general phosphatase activity. Using rotenone, a mitochondrial complex I inhibitor, they demonstrated that mitochondria appear to be one source of ROS in Bcr-Abl-transformed cells. Moreover, they suggest that Bcr-Abl signaling is amplified by simultaneous reduction in the activity of one or more phosphatases. The same group recently showed in a separate study that increased intracellular ROS levels are linked to increased glucose metabolism and this is regulated by the PI3k/Akt pathway. 10 In this study, we used an inducible Bcr-Abl expression model to show that Bcr-Abl-induced ROS are involved in regulating PI3k/Akt survival pathway via inhibition of PP1a and we identified Nox-4 as the source of ROS in TonB.210 cells. These results suggest that by reducing Bcr-Abl-driven ROS production it may be possible to increase sensitivity of Bcr-Abl-expressing cells to current chemotherapeutic intervention.
Materials and methods

Cell lines, culture conditions and treatment
TonB.210 cells are derived from the interleukin-3 (IL-3)-dependent murine pro-B cell line BaF3 and contain a doxycycline responsive promoter whereby Bcr-Abl p210 can be conditionally induced (kindly provided by permission of Dr George Daley, MIT, Cambridge, MA, USA). 11 TonB.210 cells and BaF3 cells (obtained from the DMSZ, Braunschweig, Germany) were maintained in RPMI 1640 containing 10% fetal calf serum, 2 mM L-glutamine, 1% penicillin/streptomycin and 10% Wehi-3B-conditioned medium as a source of murine IL-3, plus 1 mg/ml G418 sulfate for TonB.210 cells, in a humidified incubator at 37 1C with 5% CO 2 . TonB.210 cells were routinely incubated with 1 mg/ml doxycycline hyclate (DOX) in full IL-3-supplemented medium for indicated times to induce Bcr-Abl expression. For Nox inhibition, cells were treated with 1 mg/ml doxycycline hyclate for 24 or 48 h and 2 mM flavoprotein inhibitor diphenyleneiodonium (DPI) for 2 h before cell harvest. Cells were also treated with GSK3b inhibitor lithium chloride (10 mM for 4 h), Rac1 inhibitor NSC23766 (100 mM for 2 h) (Calbiochem, Nottingham, UK), imatinib mesylate (indicated concentration added with doxycycline for 24 or 48 h; Novartis, Basel, Switzerland), calyculin A (Cell Signaling Technology, Hertfordshire, UK), okadaic acid (Calbiochem) and hydrogen peroxide (indicated doses for 20 min) before cell harvest. Cells were treated with two different antioxidants: tiron (1,2-dihydroxybenzene-3,5-disulfonate) 12 or 3,4-dihydro-6-hydroxy-7-methoxy-2,2-dimethyl-1(2H)-benzopyran (CR-6; indicated dose for 48 h). The synthesis of CR-6 has been described elsewhere. 13 For PI3 kinase and MEK inhibition, TonB.210 were treated for 24 h with 30 mM LY294002 and 10 mM UO126, respectively (both from Cell signaling Technology). Unless otherwise stated, all reagents were from Sigma-Aldrich (Dublin, Ireland).
Measurement of Intracellular ROS levels. Following treatments, ROS levels were determined using the cell-permeable fluorogenic probe 2,7-dichlorodihydrofluorescin diacetate (H 2 DCF-DA; Invitrogen, Bio Sciences Ltd., Dun Laoghaire, Ireland) as previously described.
14 Briefly, following treatment, 50 mM H 2 DCF-DA was added for 15 min in the dark. Then, 10 000 cells were analyzed in the FL-1 channel on a FACSCalibur (BD Biosciences Europe, Oxford, UK) using Cellquest Pro software. Following siRNA transfection, cells were gated for the live population and 5000 events counted each time.
Immunoblotting. Cells were lysed with RIPA buffer (50 mM Tris-HCl (pH 7.4), 1% NP-40, 0.25% sodium deoxycholate, 150 mM NaCl, 1 mM EGTA, 1 mM sodium orthovanadate, 1 mM sodium fluoride, cocktail protease inhibitors (Roche, Welwyn, Hertforshire, UK) and 200 mM 4-(2-Aminoethyl) benzenesulfonyl fluoride hydrochloride) for 20 min on ice followed by centrifugation at 14 000 g for 15 min to remove cell debris. Equivalent amounts of protein, as determined by the Bio-Rad Protein Assay (Bio-Rad, Hemel Hempstead, UK) were resolved using SDSpolyacrylamide gel electrophoresis followed by transfer to nitrocellulose membrane (Schleicher and Schuell, Dassel, Germany) and incubated overnight with the appropriate antibodies. Membrane development was achieved using enhanced chemiluminescence (GE Healthcare, Buckinghamshire, UK). Densitometric analysis was carried out on immunoblots using ImageJ software (http://rsb.info.nih.gov/ij/index.html).
Antibodies. Primary antibodies used for immunoblotting or immunoprecipitation were anti-c-abl Ab-3 (Merck Biosciences, Nottingham, UK), phospho-Akt (ser473), phospho-GSK3b(ser9), b-catenin, phospho-Erk1/2 (thr202/tyr204), PTEN (all from Cell Signaling Technology), Mcl-1(S-19):sc-819, PP1a (E-9):sc-7482, Nox-1 (H-75), Nox-3 (A-12; all from Santa Cruz Biotechnology, Santa Cruz, CA, USA), b-actin A5441, a-tubulin T5168 (both from Sigma-Aldrich), GAPDH (Advanced Immunochemical Inc., Longbeach, CA, USA), PP2Ac clone 1D6 (catalytic subunit), PTP-1B, Nox-2 (anti-gp91-phox) from Upstate Biotechnology, Dublin, Ireland, SHP-2 (from R&D Systems, Minneapolis, MN, USA). Nox-4 antibody was a gift from Dr JD Lambeth (Emory University School of Medicine, Atlanta, GA, USA). PP1a antibody was specified by the manufacturer as not disrupting the active site when used for immunoprecipitation. All secondary antibodies were peroxidase conjugated (Amersham Biosciences, Little Chalfont, UK).
Nox siRNA and transfection. RNA interference mediated by duplexes of 21-nucleotide RNA was performed in TonB.210 cells. Different Ambion Silencer predesigned siRNA (Applied Biosystems, Warrington, UK) were used for silencing. For Nox1, the siRNA used was siRNA ID s108444; for Nox2, the siRNA ID was 160436. For Nox-4 two different siRNA were used, the siRNA named 4A in the result section is siRNA ID 184259 and 4C is siRNA ID 184261. The sequences are available from the manufacturer website. AllStars Negative Control siRNA from Qiagen (West Sussex, UK) was also used. The transfection of siRNA used the Amaxa Nucleofactor technology with the Amaxa cell optimization kit V (Amaxa, Cologne, Germany) and followed the Amaxa guidelines.
Cell survival. Cell viability was assayed by PI (SigmaAldrich) uptake according to the protocol described by Mackey et al.
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Phosphatase activity assay PP1a activity was assayed fluorimetrically using Enzolyte MFP Protein Phosphatase Assay Kit from Anaspec (Cambridge Biosciences, Cambridge, UK). Briefly, TonB.210 cells were lysed with degassed iodoacetic acid (IAA) lysis buffer (1 M Tris (pH7.5), 1% NP-40, 10% glycerol, cocktail protease inhibitors (Roche), 100 mM IAA) for 20 min at room temperature in the dark. The IAA was used to irreversibly alkylate reduced cysteine residues. PP1a was then immunoprecipitated with protein A/G agarose (Santa-Cruz Biotechnology). After washings, the beads were incubated for 10 min at 4 1C with the reducing agent DTT (10 mM) and then for 1 h at 4 1C with freshly prepared 100 mM pervanadate (as described by Huyer et al. 16 ). Pervanadate converts reduced cysteines to sulfonic acid forms. Then the protocol from the manufacturer was followed. Fluorescence was detected using the Flexstation II plate reader (Molecular Devices, Sunnyvale, CA, USA) at excitation/emission wavelengths 450/520 nm. previously showed that there is increased ROS production in a system with constitutive Bcr-Abl expression. The main aim of this work was to elucidate a mechanism for Bcr-Abl-dependent ROS signaling and to study the downstream effects. Initial experiments were carried out to demonstrate that an induction of Bcr-Abl expression resulted in increased ROS production ( Figure 1 ). This system demonstrated that TonB.210 cells expressing Bcr-Abl have a higher level of intracellular ROS compared to non-Bcr-Abl-expressing cells as measured using the ROS-sensitive probe H 2 DCF-DA. A time-dependent increase occurred between 24 and 72 h, which indicated that the increase in ROS production is Bcr-Abl dependent (Figures 1a  and b) . The same experiments were carried out on the parental cell line BaF3 to show that doxycyline treatment alone was not responsible for the production of ROS observed. There are two main sources of cellular ROS, leakage from the electron transport chain of mitochondria 17 and the Nox family proteins. Survival regulation by Bcr-Abl-induced ROS R Naughton et al
To determine the source of the ROS, a flavoprotein inhibitor commonly used as a Nox inhibitor, DPI, was added to cells 2 h before analysis of intracellular ROS. DPI incubation resulted in a reduction of ROS levels, which indicated that Nox was likely to be responsible for the production of ROS following Bcr-Abl induction (Figure 1b ). Although treatment with DPI reduces ROS production to levels below those of untreated cells, this may reflect constitutive Nox activity in untreated cells, which is then increased following Bcr-Abl induction. To further confirm that the increased ROS production was Bcr-Abl dependent we used imatinib mesylate, which is a tyrosine kinase inhibitor commonly used as a Bcr-Abl inhibitor and is marketed as Gleevec for the treatment of Philadelphia chromosome positive CML. A dose of 1 mM imatinib mesylate caused a reduction of ROS levels in doxycycline-treated cells and a 5 mM dose reduced the levels of ROS back to the levels found in untreated cells (Figure 1c ). It should be noted that neither doxycycline nor DPI or imatinib had an effect on cell survival indicating that the variation in ROS production observed is not due to a variation in numbers of cell or a byproduct of dying cells (Supplementary Figure I) . To establish whether the increased ROS production had an effect on members of a survival pathway known to be involved in Bcr-Abl-mediated resistance to apoptosis, the PI3k/Akt pathway was examined. Phosphorylation at serine 473 of Akt enhances its activity allowing phosphorylation of its downstream substrates, a major one of which is GSK3b, which in turn is inactivated when phosphorylated at serine 9 by Akt. This modification of GSK3b has a prosurvival effect as it inhibits several proapoptotic functions of GSK3b. We examined expression of pAkt(ser473) and pGSK3b(ser9). Bcr-Abl-expressing cells showed increased levels of both pAkt(ser473) and pGSK3b(ser9) whereas expression of total Akt and total GSK3b was unchanged (Figure 1d) . Interestingly, treatment with the Nox inhibitor DPI reduced phosphorylation of Akt and GSK3b at these residues. Moreover, we showed that following doxycycline treatment of the parental cell line, BaF3, Akt and GSK3b phosphorylation remain unaffected. To confirm that changes in phosphorylation of Akt and GSK3b were ROS dependent the effects of the antioxidants CR-6, a free radical scavenger and tiron, a superoxide scavenger were examined. Facs analysis of DCF fluorescence shows that Bcr-Abl-induced ROS were inhibited by treatment with both CR-6 and tiron over 48 h. Treatment with these antioxidants also inhibited phosphorylation of Akt and GSK3b in Bcr-Abl-expressing cells (Figure 1e) . Together, these results suggest that signaling by ROS molecules played a role in regulation of these key members of the PI3k/Akt pathway and therefore in survival signaling.
Downstream targets of
3 b-Catenin is a component of the Wnt signaling pathway that is deregulated in several types of cancer such as colon carcinoma and breast cancer. 18 Increased levels of b-catenin have been linked to increased survival in cancer and may also have a role in increased capacity for self-renewal in CML. 19 Phosphorylation of b-catenin by GSK3b marks it for ubiquitination and degradation therefore inhibiting the b-catenin transcriptional response. Examination of Mcl-1 and b-catenin expression showed a clear increase when Bcr-Abl expression was induced. A return to basal levels of both Mcl-1 and b-catenin was observed when ROS production was inhibited with DPI. Treatment with the GSK3b inhibitor lithium Survival regulation by Bcr-Abl-induced ROS R Naughton et al chloride caused significant stabilization of both Mcl-1 and b-catenin, which confirmed that they are both GSK3b-regulated proteins in this system (Figures 2a and b) . mRNA levels of both Mcl-1 and b-catenin are unchanged following treatment which indicates that changes seen are due to altered phosphorylation status and stabilization rather than changes in transcription Survival regulation by Bcr-Abl-induced ROS R Naughton et al (Supplementary Figure II) . In addition to regulation by the PI3k/ Akt pathway, Mcl-1 is also shown to be regulated downstream of the Ras/Raf/Mek/Erk pathway. 20 To determine the involvement of both these pathways in MCL-1 regulation, Bcr-Ablexpressing cells were treated with the MEK inhibitor UO126 and the PI3k inhibitor LY294002. Mcl-1 was downregulated following inhibition of both pathways, but to a greater extent by the PI3k inhibitor LY204002 (Figure 2c ). This indicates that although the PI3k/Akt pathway has an important role in Bcr-Abl regulation of Mcl-1, the Ras/Raf/MEK/Erk pathway is also involved. These results showed that ROS signaling not only has an effect on GSK3b activity, but that downstream targets of GSK3b, which may be involved in increased survival and oncogenesis were subsequently regulated. Further evidence that this pathway and its substrates are redox regulated was demonstrated by addition of low-dose hydrogen peroxide which caused a dosedependent increase in pAkt(ser473), pGSK3b(ser9), b-catenin and Mcl-1 (Figure 2d ).
Nox-4 is responsible for the Bcr-Abl-induced increase in ROS levels
The decrease in ROS using the Nox inhibitor DPI indicate that at least one isoform of the Nox family may be responsible for the ROS production observed on Bcr-Abl induction. As shown in Supplementary Figure III Nox-1, -2 and -4 are expressed in TonB.210 cells. To determine which of the Nox isoforms is responsible for the ROS production we employed a Rac1 inhibitor (NSC23766). Rac1 has previously been shown to be important in activation of Nox-1 and Nox-2, 21 therefore, Rac-1 inhibition should inhibit any Nox-1-and Nox-2-derived ROS. However, Bcr-Abl/doxycycline-induced ROS production following Rac-1 inhibition remains unaffected and Rac-1 inhibitor does not affect viability, which indicated that Nox-1 and -2 do not play a major role in Bcr-Abl-induced ROS (Figure 3a) . To further confirm those results, we use siRNA against Nox-1 and Nox2 (Figures 3b and c) . Western blot analysis shows that Nox-1 and -2 expression levels are decreased following siRNA treatment, however, the Bcr-Abl-induced ROS levels remain unaffected. Taken together, these results suggested that neither Nox-1 nor Nox-2 were responsible for the Bcr-Abl-induced increase in ROS levels. Nox-4 is the other Nox member expressed in these cells, which strongly suggested that Nox-4 is a key player in the Bcr-Abl-induced ROS production. To test this hypothesis, cells were transfected with siRNA against Nox-4 or with negative control siRNA over 24 and 48 h (Figure 3d ). The siRNA treatment had no effect on Bcr-Abl expression (Figure 3d , bottom panel). Examination of intracellular ROS levels following inhibition of Nox-4 with siRNA led to a block in ROS production when compared with negative control transfected cells (Figure 3e ). This indicated that the Nox-4 isoform is one of the main sources of ROS observed on Bcr-Abl induction. The effect of inhibition of Bcr-Abl-induced ROS following Nox-4 siRNA treatment on cell survival was determined by PI uptake (Figure 3f ). Cells treated with Nox-4 siRNA showed decreased survival compared to negative siRNA-treated cells.
Bcr-Abl-induced ROS exert their effects through inactivation of PP1a
An important mechanism of ROS signaling is inhibition of phosphatases through oxidation of the active site cysteine residue. 22 Bcr-Abl tyrosine kinase activity has an effect on several signaling pathways and increased phosphorylation of signaling molecules is a common event. Inactivation of phosphatases augments this effect, as an increase in phosphorylation of members of the PI3k/Akt pathway is coupled with a decrease in dephosphorylation, which in turn results in an increased survival effect. Expression of several phosphatases was examined in TonB.210 cells. PTEN, PP1a, PP2A, SHP-2 and PTP-1B were all found to be expressed (Figure 4a ). The antibody used to detect PTEN is also described to be able to detect the oxidized form of PTEN 15 but we were unable to detect oxidized PTEN in the TonB.210 cells. Treatment of TonB.210 with calyculin A, which inhibits PP1a and PP2A activity, resulted in increased phosphorylation of Akt and GSK3b whereas treatment with okadaic acid, which inhibits PP2A activity but has little effect on PP1a activity at low concentrations, 23 had no effect on Akt and GSK3b phosphorylation (Figure 4b ). This indicated that PP1a is the main phosphatase involved in regulation of the PI3k/ Akt pathway in this system. To determine if oxidative inhibition of PP1a occurs, a phosphatase activity assay was carried out. Bcr-Abl expression induced a decrease in PP1a activity and this effect was reversed on treatment with DPI. Treatment with exogenous H 2 O 2 (used as a positive control) decreased PP1a activity, which suggests an oxidative inhibition by Bcr-Ablinduced ROS (Figure 4c) . These results demonstrated a link between Bcr-Abl-induced ROS signaling and upregulation of survival pathways through increased kinase activity, with oxidative inhibition of PP1a, and possibly other phosphatases, being a key step.
Discussion
The Bcr-Abl gene product of the Philadelphia chromosome is the main feature of CML and signaling through Bcr-Abl increases survival signals in these cells. Previous studies have shown that Bcr-Abl transformation increases ROS production in cell lines in comparison to nontransformed cells as well as in primary cells from CML patients. 9, 10 It is then likely that Bcr-Abl-induced ROS level plays a role in the survival of CML cells as it is becoming Survival regulation by Bcr-Abl-induced ROS R Naughton et al more accepted that low levels of hydrogen peroxide (H 2 O 2 ) have an important signaling role, as opposed to a previous view that oxidative stress was always toxic. 24 TonB.210, a murine hematopoietic cell line, has doxycycline-dependent Bcr-Abl expression, which made it a good model to elucidate one mechanism of Bcr-Abl-dependent ROS signaling and its downstream effects.
TonB.210 cells expressing Bcr-Abl show an elevated level of ROS. This increased intracellular ROS level plays a role in regulating two major members of the PI3k/Akt pathway. Both exogenous H 2 O 2 and Bcr-Abl-induced ROS increased levels of pAkt and pGSK3b. A previous study in our lab showed that in C4 cells (a clone of 32D cells which constitutively express Bcr-Abl), Bcr-Abl upregulates PI3k p110g. 25 Increased level of this enzyme could result in a higher content PIP3 and consequently in activation of Akt signaling. In the inducible Bcr-Abl expression system TonB.210, p110g is not upregulated by Bcr-Abl (data not shown); as a result, the regulation of PI3k/Akt signaling pathway in TonB.210 is not dependent on PIP3 content. Phosphorylation of Akt increases its activity and allows it to phosphorylate GSK3b inhibiting its proapoptotic functions. Increased levels of Mcl-1, a prosurvival member of the Bcl-2 family playing a central role in apoptosis, have been linked with increased survival in cancer. The results of a recent study showed that primary CML cells express Mcl-1 in a constitutive manner and that Bcr-Abl promotes the expression of Mcl-1 through activation of the RAS/RAF/MAP kinase pathway. 20 Increased levels of b-catenin have been implicated in enhanced selfrenewal activity of CML granulocytes-macrophage progenitors. 19 Bcr is a known negative regulator of the Wnt signaling pathway by forming a complex with b-catenin and negatively regulating transcription factor such as c-Myc. Bcr-Abl, on the other hand, has lost the ability to negatively regulate the Wnt signaling pathway because Bcr-Abl phosphorylates Bcr on tyrosines, which abrogates the binding of Bcr to b-catenin. 26 Our data showing that not only GSK3b but also Mcl-1 and b-catenin, its downstream targets, were redox regulated suggest that the Bcr-Abl associated increase in intracellular ROS regulates key prosurvival proteins expression.
Interestingly, phosphorylation of PI3k pathway members by Bcr-Abl-induced ROS is inhibited by DPI, a Nox inhibitor, suggesting that at least one member of the Nox family is involved in ROS production. Activation of Nox occurs through a complex series of protein/protein interaction. Nox-2 and Nox-1 both form complexes in the membrane with p22(phox), which provides both stabilization and a docking site for organizer proteins. The p22(phox)-complexed Nox-2 and Nox-1 are dormant on their own, and their activation requires soluble supportive proteins such as a Nox organizer (p47(phox) or Noxo1) and a Nox activator (p67(phox) or Noxa1). Rac directly binds to the activators, and thus plays an essential role in the Nox-2-based oxidase containing p47(phox) and p67(phox) and directly participates in Nox-1 activation via interacting with Noxa1.
27,28 Small GTPase proteins Rac are then clearly involved in the regulation Nox-2 and Nox-1. This study showed that, in TonB.210 cells, Nox-1, Nox-2 and Nox-4 of the Nox family are expressed. The Rac inhibitor NSC23766 had no effect on Bcr-Abl-induced ROS, which indicated that Nox-1 and Nox-2 were probably not involved in Bcr-Abl induction production of ROS. Indeed, siRNA experiments enabled us to confirm that Nox-4 plays a major role in production of ROS under Bcr-Abl expression in TonB.210 cells. So far, Kim et al. 10 have shown that a mitochondrial complex I inhibitor as well as a glucose transport inhibitor can block elevated ROS levels in Bcr-Abltransformed cells, suggesting that the source of increased ROS might be related to increased glucose metabolism. Our study, using an inducible system where Bcr-Abl is expressed on induction by doxycycline, demonstrates that Nox-4 is likely to be involved in Bcr-Abl-induced ROS. The mechanism of activation of Nox-4 is not clear yet, and some studies have shown that Nox-4 is constitutively active. 29 Although, Nox-4 activation is observed under various conditions one of them being high glucose-stimulation in diabetes models. 30 Kim et al. 10 suggested that transformation by Bcr-Abl increases glucose metabolism. Taking into account those results we could Survival regulation by Bcr-Abl-induced ROS R Naughton et al suggest that an increased glucose metabolism induced by Bcr-Abl transformation activates Nox-4 and results in elevated H 2 O 2 levels in CML. The complete mechanism of Nox-4 activation by Bcr-Abl still remains to be elucidated. The fine balance between activity of kinases and phosphatases can be shifted toward increased phosphorylation of cellular proteins through an increase in cellular ROS. Moreover, inactivation of phosphatases by oxidation of their cysteine in the active site can increase phosphorylation of signaling molecules as we have observed for pAkt and pGSK3b. It is therefore interesting to determine if Bcr-Abl is not only involved in generating ROS but is also involved in regulating one or more phosphatases. PTEN has been shown to be inactivated by oxidation and is mutated in hematological malignancies. 31 PTEN is expressed in TonB.210 but does not seem to be oxidized by Bcr-Abl-induced ROS. Other phosphatase candidates that would be regulated by Bcr-Abl-induced ROS are those known to interact with Bcr-Abl kinase such as SHP-2 and PTP-1B, 32, 33 or those that are known to regulate the PI3k/Akt pathway. They could all be redox regulated as they present at least one cysteine in their active site. PP1a and PP2A can both directly inhibit Akt and GSK3b [34] [35] [36] whereas SHP-2 and PTP-1B regulate PI3k/Akt pathway upstream from Akt. We show in this study that all the phosphatases mentioned above are expressed in TonB.210 cells and that Bcr-Abl-induced ROS decreases activity of PP1a. PP1a, among other phosphatases, may provide a link between Bcr-Abl-induced ROS signaling of survival pathways and increased kinase activity. Identification of other phosphatases oxidatively regulated by Bcr-Abl-induced ROS could be interesting to target these phosphatases and thus inhibit survival pathways.
In summary, this study has demonstrated that Bcr-Ablinduced ROS upregulate the PI3k/Akt survival pathway through redox inhibition of PP1a and possibly other phosphatases. We identified Nox-4 as the source of ROS in TonB2.10 cells. As increased ROS levels are a common characteristic among many tumors, it is likely that the efficacy of standard therapy (such as imatinib mesylate treatment in the case of CML) will be increased in vivo by targeting the source of ROS. Our results illustrate the potential of targeting Nox and more specifically Nox-4 for therapeutic use in leukemia associated with Bcr-Abl as well as in other cancers.
